Vendor, Lowell, MA
Versatope Therapeutics Inc.
UEI VSMPM3EGYYA6, CAGE 7TEE7
1 award and $4,563,592 obligated between January 31, 2024 and May 29, 2025, 100% under full and open competition, against 12.0 offers on average where reported.
Industries
NAICS on the awards, by dollars.
| Research and Development in Biotechnology (except Nanobiotechnology)NAICS 541714 | $4,563,592 |
How it wins
Awards by competition, set-aside and type.
| Full and Open Competition | 1 |
| Definitive Contract | 1 |
Awards
Every award in the window, by dollars obligated.
| Contract | Awarding office | Described as | Obligated |
|---|---|---|---|
| 75N93019C00060Definitive Contract, January 31, 2024, Full and Open Competition, 12 offers | National Institutes of Health NiaidNational Institutes of Health | To Advance the Lead Universal Influenza Vaccine Candidate Through a Phase I Clinical Study and to Evaluate the Long-Term Immunogenicity withNAICS 541714, PSC AN12 | $4,563,592 |
- Places of performance
- Massachusetts
- Product and service codes
- AN12 Health R&D Services; Health Care Services; Applied Research
- Transactions
- 8 across 1 awards